{{header
 | author     = Peter Roskam
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2014
 | month      = 03
 | day        = 11
 | notes      = ''{{USBill|113|H.R.|4187}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 2
 | title      = Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 ( H.R. 4187; 113th Congress)
 | bill       = 4187
 | billtype   = hr
 | purpose    = To amend title XVIII of the Social Security Act to encourage the development and use of new antimicrobial drugs, and for other purposes.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|2d Session}}

 
{{Center|H. R. 4187}}

 
{{Center|IN THE HOUSE OF REPRESENTATIVES}}

  
{{Center|March 11, 2014}}

 
{{Center| 
[[w:Peter Roskam|Mr. Roskam]](for himself and
[[w:Danny K. Davis|Mr. Danny K. Davis of Illinois]]) introduced the following bill; which was referred to the [[w:United States House Committee on Ways and Means|Committee on Ways and Means]], and in addition to the Committee on [[w:United States House Committee on Energy and Commerce|Energy and Commerce]], for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned}}

  
{{Center|A BILL}}

 To amend title XVIII of the Social Security Act to encourage the development and use of new antimicrobial drugs, and for other purposes.   

=Section 1. Short title=

This Act may be cited as the“   Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014   ”and as the“ DISARM Act of 2014 ”. 

=Sec. 2. Encouraging the development and use of new antimicrobial drugs=



==(a) Additional payment for new antimicrobial drugs under Medicare– ==



===(1) In general– ===

   Section 1886(d)(5) of the Social Security Act ( [http://www.law.cornell.edu/uscode/text/42/1395ww 42 U.S.C. 1395ww(d)(5)] )is amended by adding at the end the following new subparagraph:

<blockquote> 
:(M) 
::(i) Effective for discharges beginning on or after October 1, 2014, the [[w:Department of Health and Human Services|Secretary]]shall, after notice and opportunity for public comment (in the publications required by subsection (e)(5) for a fiscal year or otherwise), recognize the costs of new antimicrobial drugs under the payment system established under this subsection.
::(ii) Pursuant to clause (i) , the [[w:Department of Health and Human Services|Secretary]]shall provide for additional payment to be made under this subsection with respect to discharges involving new antimicrobial drugs in the amount provided for under section 1847A for drugs and biologicals that are described in section 1842(o)(1)(C) .
::(iii) For purposes of this subparagraph, the term new antimicrobial drug means a product that is approved for use, or a product for which an indication is first approved for use, by the [[w:Food and Drug Administration|Federal Food and Drug Administration]]on or after January 1, 2014, and that—
:::(I) is indicated to treat an infection caused by, or likely to be caused by, a qualifying pathogen (as defined under  section 505E(f) of the Federal Food, Drug, and Cosmetic Act ( [http://www.law.cornell.edu/uscode/text/21/355f 21 U.S.C. 355f(f)] )) for which there is an unmet medical need and which is associated with high rates of mortality or significant patient morbidity (as determined by the [[w:Department of Health and Human Services|Secretary]], in consultation with the [[w:Centers for Disease Control and Prevention|Director of the Centers for Disease Control and Prevention]]and the infectious disease professional community); and
:::(II) is used in facilities that participate in the Antimicrobial Use and Resistance Module of the National Healthcare Safety Network of the Centers for Disease Control and Prevention (or, in the case that such Module is not available, is used in facilities that participate in such successor or similar reporting module or program relating to antimicrobials as the [[w:Department of Health and Human Services|Secretary]]shall specify to the extent available to such facilities, as determined by the [[w:Department of Health and Human Services|Secretary]]).
::(iv) Not later than July 1, 2014, the [[w:Department of Health and Human Services|Secretary]]shall first publish in the Federal Register a list of the new antimicrobial drugs. . 
</blockquote>


===(2) Budget neutrality– ===

   Section 1886(d)(3)(C) of the Social Security Act ( [http://www.law.cornell.edu/uscode/text/42/1395ww 42 U.S.C. 1395ww(d)(3)(C)] )is amended by adding at the end the following new clause:

<blockquote> 

====(iii) Maintaining budget neutrality for certain antimicrobial drugs– ====

For discharges occurring in a fiscal year beginning with fiscal year 2015, the [[w:Department of Health and Human Services|Secretary]]shall further reduce each of the average standardized amounts in an amount equal to the amount of the net additional expenditures, if any, in such fiscal year resulting from the application of paragraph (5)(M) . . 
</blockquote>


==(b) Study and report on removing barriers to development of new antimicrobial drugs– ==



===(1) Study– ===

The [[w:Government Accountability Office|Comptroller General of the United States]]shall, in consultation with the [[w:Patent and Trademark Office/Under Secretary for Intellectual Property|Director of the United States Patent and Trademark Office]], the [[w:National Institutes of Health|Director of the National Institutes of Health]], the [[w:Food and Drug Administration|Commissioner of Food and Drugs]], and the [[w:Centers for Disease Control and Prevention|Director of the Centers for Disease Control and Prevention]], conduct a study to—
:(A) identify and examine the barriers that prevent the development of new antimicrobial drugs, as defined in  section 1886(d)(5)(M)(iii) of the Social Security Act ([http://www.law.cornell.edu/uscode/text/42/1395ww 42 U.S.C. 1395ww(d)(5)(M)(iii)]); and
:(B) develop recommendations for actions to be taken in order to overcome any barriers identified under subparagraph (A) .

===(2) Report– ===

Not later than one year after the date of the enactment of this Act, the [[w:Government Accountability Office|Comptroller General]]shall submit to [[w:United States Congress|Congress]]a report on the study conducted under paragraph (1) .  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
